Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes

Table 3

Prevalence of aPL in patients with obstetric complications and healthy controls.

	Healthy controls (%)	Non-APS obstetric manifestation (%)	Pregnancy loss defined by APS criteria [1] (%)
LA	0	2 (5.3)^*	13 (8.7)^**
aCL	2 (2.3)	2 (4.8)	21 (12.4)
IgG	1 (1.2)	2 (4.8)	17 (10.1)
IgM	1 (1.2)	0	6 (3.6)
anti-β2GPI	6 (6.9)	3 (7.1)	12 (7.1)
IgG	6 (6.9)	3 (7.1)	10 (5.9)
IgM	0	0	4 (2.4)
aPS/PT	2 (2.3)	0	22 (13.0)
IgG	1 (1.2)	0	16 (9.5)
IgM	1 (1.2)	0	12 (7.1)

^*(), ^**().
aCL: anticardiolipin antibody, anti-β₂GPI: antibodies against β₂-glycoprotein I, aPS/PT: anti-phosphatidylserine/prothrombin antibodies, and LA: lupus anticoagulant.